| Window | Theses | Resolved | Wins | Win rate | Avg return | Median return |
|---|---|---|---|---|---|---|
| 1d | 6 | 6 | 2 | 33% | +0.7% | -0.8% |
| 3d | 7 | 7 | 6 | 86% | +4.2% | +4.9% |
| 1w | 7 | 7 | 6 | 86% | +6.0% | +8.1% |
| 1m | 7 | 7 | 2 | 29% | -7.6% | -11.3% |
| 3m | 7 | 7 | 0 | 0% | -12.8% | -10.8% |
| 6m | 0 | 0 | 0 | — | — | — |
| 1y | 0 | 0 | 0 | — | — | — |
Past performance does not predict future results. Informational only, not investment advice.
AI-driven biotech sector is breaking out; Prime is positioned at the forefront of this healthcare AI theme that should see significant growth as rare disease treatments accelerate. The author believes the AI biotech trend is just beginning and PRME will participate in major upside.
Prime Medicine is a leader in genomic editing breaking out of a large base on strong volume with bullish technical setup. Author expects significant upside movement to $10+ in the near term as part of a broader biotech/genomic editing sector breakout theme.
MBLY is Intel's robotics division with strong upside potential. Author averaged up and doubled exposure, betting on the underlying technology and market opportunity.
Investor has increased position size 5x after community discussion and endorsement, viewing Mobileye as a solid investment opportunity with near-term upside potential.
Mobileye is positioned at the center of a secular robotics boom with strong backing from Intel. Industry leaders like Musk and Huang view robotics as the next massive growth frontier after AI, with humanoid robots and autonomous vehicles set to integrate across industries. Mobileye's exclusive focus on robotics, recent earnings beat, share buyback, and 200m+ chips sold position it to capitalize.
Intel owns Mobileye and is focusing exclusively on robotics, humanoid robotics, and autonomous driving, positioning it to capture value from the robotics TAM that industry leaders view as larger than AI/LLM. Indirect play on the physical AI theme through Mobileye partnership.
Mobileye is a robotics/autonomous driving chip play backed by Intel, positioned to benefit from the emerging physical AI TAM which Musk and Huang believe exceeds AI/LLM. Recent earnings beat, share buyback, 200m+ chips sold, and cheap call options offer attractive risk/reward as robotics adoption accelerates.
End of results.